Skip to main
IMNM
IMNM logo

Immunome (IMNM) Stock Forecast & Price Target

Immunome (IMNM) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunome Inc. is advancing its clinical pipeline, with a strong focus on oncology and infectious diseases, and is preparing for the RINGSIDE Phase 3 data involving Varegacestat, which is viewed as potentially differentiated in its class. The company's strategy aims to deliver demonstrably superior outcomes in objective response rates (ORR), tumor volume, and symptom reductions, which are crucial for commercial success. This strategic positioning, along with the promising development of multiple assets, contributes to a favorable risk/reward outlook for the company's stock.

Bears say

Immunome Inc has experienced a significant decline in its stock performance, with shares underperforming by 55% since the announcement of the varegacestat acquisition on February 6, 2024. The company's bear case scenario suggests a potential share value of approximately $5-$7 if varegacestat proves inferior compared to competing treatments and fails to gain approval or achieves minimal sales. Additionally, Immunome faces various risks including research and development challenges, regulatory hurdles, competition, and the likelihood of lower than expected product sales, all of which contribute to a negative outlook on its financial prospects.

Immunome (IMNM) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunome and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunome (IMNM) Forecast

Analysts have given Immunome (IMNM) a Buy based on their latest research and market trends.

According to 9 analysts, Immunome (IMNM) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunome (IMNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.